The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors ...
Trastuzumab deruxtecan (T-DXd; Enhertu), is a HER2-targeting ADC that is used in ET-treated HER2-low or HER2-ultralow disease ...
The New York Times, attacked by President Donald Trump for reporting about his physical condition, said on Wednesday that it ...
Among more than 4,000 patients with hormone receptor (HR)-positive disease, 3-year invasive disease-free survival (IDFS) ...
The FDA on Tuesday approved etuvetidigene autotemcel (Waskyra) as the first cell-based gene therapy for patients 6 months and ...
The drugs are essentially laboratory-made versions of natural antibodies that help the immune system fight off RSV. The FDA ...
A House hearing Wednesday on the topic of how technology can help lower healthcare costs was sidetracked almost immediately ...
Suhasini Ravi, JD, MPH, is a senior associate at the Center for Health Policy and the Law at the O'Neill Institute in ...
Rep. Haley Stevens (D-Mich.) announced that she introduced articles of impeachment against HHS Secretary Robert F. Kennedy Jr ...
"Our findings suggest that while antidepressants are effective in preventing depressive relapses, they do not need to be a ...
Based on initial positive results from HOPE-B, etranacogene dezaparvovec became the first gene therapy approved for adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback